# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ann Richards (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML019-SYN-TD
- Date: 1997-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Teague, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week bone health review. **S**

## History of present illness

Ms. Richards returns four weeks after her intake visit. She takes vitamin D3 1971 units every day. She has added yogurt, cheese, and calcium-fortified orange juice, and her three-day food record shows about 1200 mg of calcium a day. She keeps walking and lifting weights and has had no falls. She did not collect the 24-hour urine sample before this visit because she was traveling for three weeks. She saw the endocrinologist this morning. Her balance and strength program with the physical therapist starts next week, and she has a routine dental examination booked next month. She has had no alcohol and no cravings. **S**

| Element | Detail |
|---|---|
| Calcium intake | About 1200 mg a day from food by three-day record |
| Vitamin D | D3 1971 units daily, no missed doses |
| Falls | None |
| Pending tests | 24-hour urine calcium not yet collected |
| Recovery | No alcohol; no cravings |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Musculoskeletal | Negative | No back pain, new bone pain, or fracture; the healed hand is not painful |
| Neurological | Negative | No dizziness or unsteadiness |
| Gastrointestinal | Negative | No constipation since adding dairy foods |
| Psychiatric | Negative | Mood good; no cravings; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 50 mcg (1971 units) oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/74 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 66.2 kg; BMI 24.6 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Well and animated; weight 66.2 kg |
| Spine | No tenderness or kyphosis; occiput touches the wall |
| Gait and balance | Gait steady; tandem stance 8 seconds, unchanged |
| Mouth | Good dentition; no exposed bone or gum swelling |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Low bone mass with high fracture risk by FRAX** (M85.89). Lumbar spine T-score -2.3, femoral neck -2.0, and total hip -1.7: low bone mass, not osteoporosis by T-score. FRAX 22 percent for a major osteoporotic fracture and 3.6 percent for hip fracture, both above the treatment thresholds of 20 and 3 percent. Secondary-causes tests are normal apart from vitamin D of 24 ng/mL, now being repleted; the 24-hour urine calcium is outstanding. The endocrinologist agrees that treatment is indicated and recommends zoledronic acid once vitamin D is 30 ng/mL or more and the dental examination is done. **S**
   - Continue vitamin D3 1971 units daily and about 1200 mg of calcium a day from food.
   - Collect the 24-hour urine calcium before the three-month visit; container and written instructions given again.
   - Recheck 25-hydroxyvitamin D, calcium, and creatinine at three months; first zoledronic acid infusion that day if they are in range.
   - Routine dental examination next month.
2. **History of falls** (Z91.81). No falls since intake; balance below normal (tandem stance 8 seconds). **S**
   - Balance and strength program with the physical therapist from next week, twice a week for eight weeks.
3. **Alcohol use disorder in sustained remission** (F10.21). No alcohol or cravings. Safety reviewed: no thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone. **S**
   - Continue the recovery check at each visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Secondary-causes work-up | At diagnosis: calcium, albumin, phosphate, magnesium, alkaline phosphatase, creatinine and eGFR, PTH, 25-hydroxyvitamin D, TSH, blood count, and 24-hour urine calcium | Up to date | At intake: calcium 9.4 mg/dL, albumin 4.2 g/dL, phosphate 3.5, magnesium 2.0, alkaline phosphatase 84 U/L, creatinine 0.8 mg/dL (eGFR 81), PTH 54 pg/mL, TSH 1.9, hemoglobin 13.3, all normal; 25-hydroxyvitamin D 24 ng/mL, low |
| Laboratory | 24-hour urine calcium | At diagnosis, before starting therapy | Deferred | Ordered at intake to be collected before today; not collected because she was traveling. Deviation from the baseline work-up. No harm so far, because no drug has been started. Corrective action: container and instructions given again, and the result is required before the first infusion |
| Laboratory | 25-hydroxyvitamin D | At baseline; after repletion until 30 ng/mL or more; then yearly | Due | 24 ng/mL at intake; recheck at three months, before the first infusion |
| Laboratory | Serum calcium before each intravenous antiresorptive dose | Before each zoledronic acid dose | Due | Planned at three months, before the first infusion |
| Laboratory | Bone-turnover marker (fasting serum CTX) | Baseline, then 3 to 6 months after starting or changing therapy | Up to date | 560 pg/mL at intake; repeat three months after the first dose |
| Imaging | Central DXA of the spine and hip | Every 1 to 2 years on therapy until stable, on the same scanner | Up to date | Baseline at intake; repeat two years after starting therapy |
| Imaging | Vertebral fracture assessment | At baseline with a recent low-trauma fracture, height loss of 4 cm or more, or a T-score of -2.5 or lower | Up to date | Done at intake for the recent low-trauma fracture: no vertebral fracture |
| Examination | Standing height by stadiometer | Yearly; vertebral imaging again if height falls 2 cm or more | Up to date | 164.0 cm at intake |
| Examination | Fall-risk screen | Yearly, and with any fall | Up to date | At intake: Timed Up and Go 11 seconds, tandem stance 8 seconds, chair stand 11; fall with fracture in the past year |
| Survey | FRAX 10-year fracture risk | At baseline and when risk factors change | Up to date | 22 percent major osteoporotic and 3.6 percent hip at intake; no change in risk factors |
| Survey | Calcium intake assessment | At baseline and yearly | Completed today | About 1200 mg a day from food by three-day record, up from about 800 mg |
| Medication safety | Dental examination before an antiresorptive | Before starting a bisphosphonate or denosumab | Due | Routine dental examination booked next month, before the first infusion |
| Medication safety | Drug-holiday eligibility | After 3 yearly zoledronic acid doses or 5 years of an oral bisphosphonate | Not indicated | No drug started yet |
| Medication safety | Denosumab continuity check | Every 6 months on denosumab | Not indicated | Not on denosumab |
| Referral | Endocrinology consultation | When the diagnosis, risk category, or drug choice needs specialist review | Completed today | Seen today; treatment indicated; zoledronic acid recommended after vitamin D repletion |
| Self-management | Balance and strength exercise program | With a history of falls or impaired balance | Referred | Physical therapist program begins next week |
| Self-management | Recovery check (alcohol, cravings, stress) | Every visit | Completed today | No alcohol; no cravings |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone |

## Goal progress

- Total calcium intake of about 1200 mg a day, mostly from food, by the four-week visit. Outcome by 1997-03-10: About 1200 mg a day from food by her own three-day food record. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more before the first infusion. In progress; target 1997-05-12. **S**
- First zoledronic acid dose by the three-month visit, with normal calcium and kidney function and a dental check done. In progress; target 1997-05-12. **S**
- Complete the eight-week balance and strength program, with no falls through six months. In progress; target 1997-08-11. **S**
- Serum CTX at least 30 percent lower three months after the first dose. In progress; target 1997-08-11. **S**
- Sustained remission from alcohol use disorder throughout the episode. In progress; target 1997-08-11. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026), Aether Forge
- The clinician's guide to prevention and treatment of osteoporosis (2022), Bone Health and Osteoporosis Foundation (LeBoff MS et al., Osteoporos Int 2022;33(10):2049-2102)
- American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020), AACE/ACE (Camacho PM et al., Endocr Pract 2020;26(Suppl 1):1-46)
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019), Endocrine Society (Eastell R et al., J Clin Endocrinol Metab 2019;104(5):1595-1622)
- STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026), Centers for Disease Control and Prevention
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Balance program from next week. Dental examination next month. 24-hour urine collection before the next visit. Bone health review in two months with pre-infusion tests and the first infusion. **S**
- Next scheduled visit 1997-05-12: three-month bone health review and first zoledronic acid infusion. **S**
